PERPHENAZINE

Details

Stereochemistry	ACHIRAL
Molecular Formula	C21H26ClN3OS
Molecular Weight	403.969
Optical Activity	NONE
Defined Stereocenters	0 / 0
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

OCCN1CCN(CCCN2C3=CC=CC=C3SC4=CC=C(Cl)C=C24)CC1

InChI

InChIKey=RGCVKNLCSQQDEP-UHFFFAOYSA-N

InChI=1S/C21H26ClN3OS/c22-17-6-7-21-19(16-17)25(18-4-1-2-5-20(18)27-21)9-3-8-23-10-12-24(13-11-23)14-15-26/h1-2,4-7,16,26H,3,8-15H2

HIDE SMILES / InChI

Description
Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2013/089683s024lbl.pdf | http://apm.amegroups.com/article/view/1039/1266

Perphenazine is a relatively high potency phenothiazine that blocks dopamine 2 receptors predominantly, but also may possess antagonist actions at histamine 1 and cholinergic M1 and alpha 1 adrenergic receptors in the vomiting center leading to reduced nausea and vomiting. The drug was approved by FDA for the treatment of schizophrenia and control of severe nausea and vomiting (either alone or in combination with amitriptyline hydrochloride). Perphenazine is extensively hepatic to metabolites via sulfoxidation, hydroxylation, dealkylation, and glucuronidation; primarily metabolized by CYP2D6 to N-dealkylated perphenazine, perphenazine sulfoxide, and 7-hydroxyperphenazine (active metabolite with 70% of the activity of perphenazine) and excreted in the urine and feces.

CNS Activity

Approval Year

Targets

Primary Target	Pharmacology	Potency
D(2) dopamine receptor 58 Target ID: P14416 Gene ID: 1813.0 Gene Symbol: DRD2 Target Organism: Homo sapiens (Human) Sources: http://apm.amegroups.com/article/view/1039/1266	Antagonist 2849	0.16 nM [Ki]
Histamine H1 receptor 316 Target ID: P35367 Gene ID: 3269.0 Gene Symbol: HRH1 Target Organism: Homo sapiens (Human) Sources: http://apm.amegroups.com/article/view/1039/1266	Antagonist 2849	8.0 nM [Kd]
Muscarinic acetylcholine receptor M1 168 Target ID: P11229 Gene ID: 1128.0 Gene Symbol: CHRM1 Target Organism: Homo sapiens (Human) Sources: http://apm.amegroups.com/article/view/1039/1266	Antagonist 2849	1.5 µM [Kd]
Adrenergic receptor alpha-1 171 Target ID: CHEMBL2094251 Sources: http://apm.amegroups.com/article/view/1039/1266	Antagonist 2849	10.0 nM [Ki]

Conditions

Condition	Modality	Highest Phase	Product
Nausea 63 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2013/089683s024lbl.pdf	Preventing	Approved 8583	PERPHENAZINE Approved Use Perphenazine is indicated for use in the treatment of schizophrenia and for the control of severe nausea and vomiting in adults. Launch Date 1988
Vomiting 38 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2013/089683s024lbl.pdf	Preventing	Approved 8583	PERPHENAZINE Approved Use Perphenazine is indicated for use in the treatment of schizophrenia and for the control of severe nausea and vomiting in adults. Launch Date 1988
Schizophrenia 305 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2013/089683s024lbl.pdf	Primary	Approved 8583	PERPHENAZINE Approved Use Perphenazine is indicated for use in the treatment of schizophrenia and for the control of severe nausea and vomiting in adults. Launch Date 1988
Anxiety 275 Sources: https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=e2937445-c015-c9a5-52f8-a2959da97290	Primary	Approved 8583	PERPHENAZINE AND AMITRIPTYLINE HYDROCHLORIDE Approved Use Perphenazine and amitriptyline hydrochloride tablets are recommended for treatment of (1) patients with moderate to severe anxiety and/or agitation and depressed mood, (2) patients with depression in whom anxiety and/or agitation are severe, and (3) patients with depression and anxiety in association with chronic physical disease. In many of these patients, anxiety masks the depressive state so that, although therapy with a tranquilizer appears to be indicated, the administration of a tranquilizer alone will not be adequate. Launch Date 1988
Depression 240 Sources: https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=e2937445-c015-c9a5-52f8-a2959da97290	Primary	Approved 8583	PERPHENAZINE AND AMITRIPTYLINE HYDROCHLORIDE Approved Use Perphenazine and amitriptyline hydrochloride tablets are recommended for treatment of (1) patients with moderate to severe anxiety and/or agitation and depressed mood, (2) patients with depression in whom anxiety and/or agitation are severe, and (3) patients with depression and anxiety in association with chronic physical disease. In many of these patients, anxiety masks the depressive state so that, although therapy with a tranquilizer appears to be indicated, the administration of a tranquilizer alone will not be adequate. Launch Date 1988

C_max

Value	Dose	Analyte	Population
0.546 ng/mL REVIEW https://www.accessdata.fda.gov/drugsatfda_docs/anda/98/40226_Perphenazaine_Bioeqr.pdf	16 mg single, oral dose: 16 mg route of administration: Oral experiment type: SINGLE co-administered:	PERPHENAZINE plasma	Homo sapiens population: UNKNOWN age: UNKNOWN sex: UNKNOWN food status: UNKNOWN
984 pg/mL DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/label/2013/089683s024lbl.pdf	4 mg 3 times / day steady-state, oral dose: 4 mg route of administration: Oral experiment type: STEADY-STATE co-administered:	PERPHENAZINE plasma	Homo sapiens population: UNKNOWN age: UNKNOWN sex: UNKNOWN food status: UNKNOWN
509 pg/mL DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/label/2013/089683s024lbl.pdf	4 mg 3 times / day steady-state, oral dose: 4 mg route of administration: Oral experiment type: STEADY-STATE co-administered:	7-HYDROXYPERPHENAZINE plasma	Homo sapiens population: UNKNOWN age: UNKNOWN sex: UNKNOWN food status: UNKNOWN

AUC

Value	Dose	Co-administered	Analyte	Population
6.673 ng × h/mL REVIEW https://www.accessdata.fda.gov/drugsatfda_docs/anda/98/40226_Perphenazaine_Bioeqr.pdf	16 mg single, oral dose: 16 mg route of administration: Oral experiment type: SINGLE co-administered:		PERPHENAZINE plasma	Homo sapiens population: UNKNOWN age: UNKNOWN sex: UNKNOWN food status: UNKNOWN

T_1/2

Value	Dose	Analyte	Population
9.12 h REVIEW https://www.accessdata.fda.gov/drugsatfda_docs/anda/98/40226_Perphenazaine_Bioeqr.pdf	16 mg single, oral dose: 16 mg route of administration: Oral experiment type: SINGLE co-administered:	PERPHENAZINE plasma	Homo sapiens population: UNKNOWN age: UNKNOWN sex: UNKNOWN food status: UNKNOWN
12 h DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/label/2013/089683s024lbl.pdf	4 mg 3 times / day steady-state, oral dose: 4 mg route of administration: Oral experiment type: STEADY-STATE co-administered:	PERPHENAZINE plasma	Homo sapiens population: UNKNOWN age: UNKNOWN sex: UNKNOWN food status: UNKNOWN
18.8 h DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/label/2013/089683s024lbl.pdf	4 mg 3 times / day steady-state, oral dose: 4 mg route of administration: Oral experiment type: STEADY-STATE co-administered:	7-HYDROXYPERPHENAZINE plasma	Homo sapiens population: UNKNOWN age: UNKNOWN sex: UNKNOWN food status: UNKNOWN

F_unbound

Value	Dose	Co-administered	Analyte	Population
9% DRUG LABEL https://www.glowm.com/resources/glowm/cd/pages/drugs/p024.html	unknown, unknown		PERPHENAZINE unknown	Homo sapiens population: UNKNOWN age: UNKNOWN sex: UNKNOWN food status: UNKNOWN

Doses

Dose	Population	Adverse events
0.93 g single, oral Overdose Dose: 0.93 g Route: oral Route: single Dose: 0.93 g Sources: https://pubmed.ncbi.nlm.nih.gov/21264008	unhealthy, 42 Health Status: unhealthy Age Group: 42 Sex: M Sources: https://pubmed.ncbi.nlm.nih.gov/21264008	Disc. AE: QT interval prolonged, Hypothermia... AEs leading to discontinuation/dose reduction: QT interval prolonged Hypothermia Loss of consciousness PR interval prolonged QRS prolonged Sources: https://pubmed.ncbi.nlm.nih.gov/21264008
200 mg single, oral Overdose Dose: 200 mg Route: oral Route: single Dose: 200 mg Sources: https://pubmed.ncbi.nlm.nih.gov/1729053	unhealthy, 48 Health Status: unhealthy Age Group: 48 Sex: F Sources: https://pubmed.ncbi.nlm.nih.gov/1729053	Disc. AE: Coma, Hypothermia... AEs leading to discontinuation/dose reduction: Coma Hypothermia Tachycardia Miosis Sources: https://pubmed.ncbi.nlm.nih.gov/1729053
30 mg 1 times / day multiple, intramuscular Recommended Dose: 30 mg, 1 times / day Route: intramuscular Route: multiple Dose: 30 mg, 1 times / day Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2002/10775s311213s24lbl.pdf	unhealthy Health Status: unhealthy Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2002/10775s311213s24lbl.pdf	Disc. AE: Tardive dyskinesia... AEs leading to discontinuation/dose reduction: Tardive dyskinesia Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2002/10775s311213s24lbl.pdf
30 mg 1 times / day multiple, intramuscular Recommended Dose: 30 mg, 1 times / day Route: intramuscular Route: multiple Dose: 30 mg, 1 times / day Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2002/10775s311213s24lbl.pdf	unhealthy Health Status: unhealthy Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2002/10775s311213s24lbl.pdf	Disc. AE: Neuroleptic malignant syndrome... AEs leading to discontinuation/dose reduction: Neuroleptic malignant syndrome Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2002/10775s311213s24lbl.pdf
64 mg 1 times / day multiple, oral Recommended Dose: 64 mg, 1 times / day Route: oral Route: multiple Dose: 64 mg, 1 times / day Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2002/10775s311213s24lbl.pdf	unhealthy Health Status: unhealthy Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2002/10775s311213s24lbl.pdf	Disc. AE: Tardive dyskinesia... AEs leading to discontinuation/dose reduction: Tardive dyskinesia Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2002/10775s311213s24lbl.pdf
64 mg 1 times / day multiple, oral Recommended Dose: 64 mg, 1 times / day Route: oral Route: multiple Dose: 64 mg, 1 times / day Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2002/10775s311213s24lbl.pdf	unhealthy Health Status: unhealthy Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2002/10775s311213s24lbl.pdf	Disc. AE: Neuroleptic malignant syndrome... AEs leading to discontinuation/dose reduction: Neuroleptic malignant syndrome Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2002/10775s311213s24lbl.pdf
20 mg single, intramuscular Studied dose Dose: 20 mg Route: intramuscular Route: single Dose: 20 mg Sources: https://pubmed.ncbi.nlm.nih.gov/3588517/	unhealthy Health Status: unhealthy Sources: https://pubmed.ncbi.nlm.nih.gov/3588517/	Disc. AE: Neuroleptic malignant syndrome... AEs leading to discontinuation/dose reduction: Neuroleptic malignant syndrome Sources: https://pubmed.ncbi.nlm.nih.gov/3588517/

AEs

AE	Significance	Dose	Population
Hypothermia	Disc. AE	0.93 g single, oral Overdose Dose: 0.93 g Route: oral Route: single Dose: 0.93 g Sources: https://pubmed.ncbi.nlm.nih.gov/21264008	unhealthy, 42 Health Status: unhealthy Age Group: 42 Sex: M Sources: https://pubmed.ncbi.nlm.nih.gov/21264008
Loss of consciousness	Disc. AE	0.93 g single, oral Overdose Dose: 0.93 g Route: oral Route: single Dose: 0.93 g Sources: https://pubmed.ncbi.nlm.nih.gov/21264008	unhealthy, 42 Health Status: unhealthy Age Group: 42 Sex: M Sources: https://pubmed.ncbi.nlm.nih.gov/21264008
PR interval prolonged	Disc. AE	0.93 g single, oral Overdose Dose: 0.93 g Route: oral Route: single Dose: 0.93 g Sources: https://pubmed.ncbi.nlm.nih.gov/21264008	unhealthy, 42 Health Status: unhealthy Age Group: 42 Sex: M Sources: https://pubmed.ncbi.nlm.nih.gov/21264008
QRS prolonged	Disc. AE	0.93 g single, oral Overdose Dose: 0.93 g Route: oral Route: single Dose: 0.93 g Sources: https://pubmed.ncbi.nlm.nih.gov/21264008	unhealthy, 42 Health Status: unhealthy Age Group: 42 Sex: M Sources: https://pubmed.ncbi.nlm.nih.gov/21264008
QT interval prolonged	Disc. AE	0.93 g single, oral Overdose Dose: 0.93 g Route: oral Route: single Dose: 0.93 g Sources: https://pubmed.ncbi.nlm.nih.gov/21264008	unhealthy, 42 Health Status: unhealthy Age Group: 42 Sex: M Sources: https://pubmed.ncbi.nlm.nih.gov/21264008
Coma	Disc. AE	200 mg single, oral Overdose Dose: 200 mg Route: oral Route: single Dose: 200 mg Sources: https://pubmed.ncbi.nlm.nih.gov/1729053	unhealthy, 48 Health Status: unhealthy Age Group: 48 Sex: F Sources: https://pubmed.ncbi.nlm.nih.gov/1729053
Hypothermia	Disc. AE	200 mg single, oral Overdose Dose: 200 mg Route: oral Route: single Dose: 200 mg Sources: https://pubmed.ncbi.nlm.nih.gov/1729053	unhealthy, 48 Health Status: unhealthy Age Group: 48 Sex: F Sources: https://pubmed.ncbi.nlm.nih.gov/1729053
Miosis	Disc. AE	200 mg single, oral Overdose Dose: 200 mg Route: oral Route: single Dose: 200 mg Sources: https://pubmed.ncbi.nlm.nih.gov/1729053	unhealthy, 48 Health Status: unhealthy Age Group: 48 Sex: F Sources: https://pubmed.ncbi.nlm.nih.gov/1729053
Tachycardia	Disc. AE	200 mg single, oral Overdose Dose: 200 mg Route: oral Route: single Dose: 200 mg Sources: https://pubmed.ncbi.nlm.nih.gov/1729053	unhealthy, 48 Health Status: unhealthy Age Group: 48 Sex: F Sources: https://pubmed.ncbi.nlm.nih.gov/1729053
Tardive dyskinesia	Disc. AE	30 mg 1 times / day multiple, intramuscular Recommended Dose: 30 mg, 1 times / day Route: intramuscular Route: multiple Dose: 30 mg, 1 times / day Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2002/10775s311213s24lbl.pdf	unhealthy Health Status: unhealthy Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2002/10775s311213s24lbl.pdf
Neuroleptic malignant syndrome	Disc. AE	30 mg 1 times / day multiple, intramuscular Recommended Dose: 30 mg, 1 times / day Route: intramuscular Route: multiple Dose: 30 mg, 1 times / day Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2002/10775s311213s24lbl.pdf	unhealthy Health Status: unhealthy Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2002/10775s311213s24lbl.pdf
Tardive dyskinesia	Disc. AE	64 mg 1 times / day multiple, oral Recommended Dose: 64 mg, 1 times / day Route: oral Route: multiple Dose: 64 mg, 1 times / day Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2002/10775s311213s24lbl.pdf	unhealthy Health Status: unhealthy Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2002/10775s311213s24lbl.pdf
Neuroleptic malignant syndrome	Disc. AE	64 mg 1 times / day multiple, oral Recommended Dose: 64 mg, 1 times / day Route: oral Route: multiple Dose: 64 mg, 1 times / day Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2002/10775s311213s24lbl.pdf	unhealthy Health Status: unhealthy Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2002/10775s311213s24lbl.pdf
Neuroleptic malignant syndrome	Disc. AE	20 mg single, intramuscular Studied dose Dose: 20 mg Route: intramuscular Route: single Dose: 20 mg Sources: https://pubmed.ncbi.nlm.nih.gov/3588517/	unhealthy Health Status: unhealthy Sources: https://pubmed.ncbi.nlm.nih.gov/3588517/

Overview

CYP3A4	CYP2C9	CYP2D6	hERG
substrate 1946	inhibitor 2438	substrate 1388	inhibitor 2217

OverviewOther

Other Inhibitor	Other Substrate	Other Inducer
CYP2B6 926 CYP1A2 2153 CYP2C19 2057 CYP3A 227 P-gp 1741 UGT2B10 31 K+ channels 73 Nav1.5 116	P-gp 2052 CYP2C19 1119	MRP1 74

Drug as perpetrator

Target	Modality	Activity
CYP2C19 2141	inhibitor 4027 Sources: https://pubmed.ncbi.nlm.nih.gov/10460810/ Page: abstract	no
CYP2C9 2497	inhibitor 4027 Sources: https://pubmed.ncbi.nlm.nih.gov/10460810/ Page: abstract	no
CYP3A 317	inhibitor 4027 Sources: https://pubmed.ncbi.nlm.nih.gov/10460810/ Page: abstract	no
CYP2B6 1160	inhibitor 4027 Sources: https://pubmed.ncbi.nlm.nih.gov/10460810/ Page: abstract	yes [IC50 1.5 uM]
K+ channels 73	inhibitor 4027 Sources: https://link.springer.com/article/10.1007/s00210-009-0420-1 Page: abstract	yes [IC50 38.2 uM]
UGT2B10 33	inhibitor 4027 Sources: https://dmd.aspetjournals.org/content/44/3/378.short Page: 42.0	yes [IC50 66.2 uM]
CYP1A2 2333	inhibitor 4027 Sources: https://pubmed.ncbi.nlm.nih.gov/10460810/ Page: abstract	yes [Ki 65.1 uM]
MRP1 232	inducer 1966 Sources: https://iv.iiarjournals.org/content/23/6/943.short Page: 945.0	yes
P-gp 1932	inhibitor 4027 Sources: https://link.springer.com/article/10.1007%2Fs40263-012-0008-z Page: 962.0	yes

Drug as victim

Target	Modality	Activity
CYP2C19 1119	substrate 4014 Sources: https://link.springer.com/article/10.1007%2Fs40263-012-0008-z Page: 961.0	yes
CYP2D6 1388	substrate 4014 Sources: https://journals.sagepub.com/doi/abs/10.1177/0269881104047278 Page: 510.0	yes
CYP3A4 1946	substrate 4014 Sources: https://link.springer.com/article/10.1007%2Fs40263-012-0008-z Page: 961.0	yes
P-gp 2052	substrate 4014 Sources: https://link.springer.com/article/10.1007%2Fs40263-012-0008-z Page: 961.0	yes

Tox targets

Target	Modality	Activity	Metabolite	Clinical evidence
Nav1.5 119	inhibitor 2237 Sources: https://www.sciencedirect.com/science/article/pii/S0002914917310421 Page: 1033.0
hERG 2263	inhibitor 2237 Sources: https://www.tandfonline.com/doi/abs/10.1081/DCT-200064482 Page: abstract

Sourcing

Vendor/Aggregator	ID	URL
ChEBI	CHEBI:8028	https://www.ebi.ac.uk/chebi/searchId.do?chebiId=CHEBI:8028
ChemicalBook	CB6687009	https://www.chemicalbook.com/ChemicalProductProperty_EN_CB6687009
eMolecules	593689	https://www.emolecules.com/cgi-bin/more?vid=593689
MolPort	MolPort-001-727-942	https://www.molport.com/shop/molecule-link/MolPort-001-727-942
ZINC	ZINC000019228902	http://zinc15.docking.org/substances/ZINC000019228902

PubMed

Title	Date	PubMed
The bucco-linguo-masticatory syndrome as a side-effect of neuroleptics therapy.	1967	4383787
Phenothiazines in early labour.	1967 Feb 11	6017500
Idiosyncratic responses to phenothiazines.	1972 Jan 22	5058744
The mechanism of the potentiating effect of antidepressant drugs on the protective influenc oe of diphenhydramine in experimental catatonia. The role of histamine.	1974	4477392
Letter: Side-effects of perphenazine.	1975 Jun 21	48972
Drug-induced dystonia.	1975 May	1119613
Drug-induced anaphylaxis, convulsions, deafness, and extrapyramidal symptoms.	1977 Mar 12	65671
Electrophysiologic studies of perphenazine and protriptyline in a patient with psychotropic drug-induced ventricular fibrillation.	1979 Aug	463940
Actions of clonidine on convulsions and behaviour.	1981 Jul	7305545
Unique sensitivity of Hb Zürich to oxidative injury by phenazopyridine: reversal of the effects by elevating carboxyhemoglobin levels in vivo and in vitro.	1983 Jun	6859031
Effect of different neuroleptics in tardive dyskinesia and parkinsonism. A video-controlled multicenter study with chlorprothixene, perphenazine, haloperidol and haloperidol + biperiden. Nordic Dyskinesia Study Group.	1986	2880362
Tourette-like syndrome following low dose short-term neuroleptic treatment.	1986 May	3459568
Zuclopenthixol and perphenazine in patients with acute psychotic states. A double-blind multicentre study.	1987 Jul	3615572
Neurologic approach to drug-induced movement disorders: a study of 125 patients.	1990 May	1971459
D1/D2 dopamine and N-methyl-D-aspartate (NMDA) receptor participation in experimental catalepsy in rats.	1992	1365866
Association of plasma homovanillic acid with behavioral symptoms in patients diagnosed with dementia: a preliminary report.	1997 Dec 1	9386853
Olanzapine use in women with antipsychotic-induced hyperprolactinemia.	1998 Oct	9766782
Acquired aplastic anemia secondary to perphenazine.	1999 Autumn	10495369
Perphenazine-induced hiccups.	1999 Mar	10333169
[Diabetes mellitus after treatment with clozapine].	2000 Feb 26	10719549
Antipsychotic-induced extrapyramidal syndromes. Risperidone compared with low- and high-potency conventional antipsychotic drugs.	2001 Jul	11549212
Quercetin potentiates L-Dopa reversal of drug-induced catalepsy in rats: possible COMT/MAO inhibition.	2003 Jun	12711835
H1-histamine receptor affinity predicts short-term weight gain for typical and atypical antipsychotic drugs.	2003 Mar	12629531
An unexpected increase of troponin I after perphenazine depot injection.	2004 Feb	14742781
Stable expression of constitutively activated mutant h5HT6 and h5HT7 serotonin receptors: inverse agonist activity of antipsychotic drugs.	2005 May	15821958
Clinical characteristics and psychopathological profile of patients with vulvodynia: an observational and descriptive study.	2008	18032895
Identification of selected therapeutic agents as inhibitors of carboxylesterase 1: potential sources of metabolic drug interactions.	2010 Apr 11	20097249
Identification of human Ether-à-go-go related gene modulators by three screening platforms in an academic drug-discovery setting.	2010 Dec	21158687
A cell protection screen reveals potent inhibitors of multiple stages of the hepatitis C virus life cycle.	2010 Feb 23	20142494
Profiling of a prescription drug library for potential renal drug-drug interactions mediated by the organic cation transporter 2.	2011 Jul 14	21599003
Selective inhibition of hepatitis C virus infection by hydroxyzine and benztropine.	2014 Jun	24709263

Patents

Sample Use Guides

In Vivo Use Guide

Moderately disturbed nonhospitalized patients with schizophrenia: 4 to 8 mg t.i.d. initially; reduce as soon as possible to minimum effective dosage. Hospitalized patients with schizophrenia: 8 to 16 mg b.i.d. to q.i.d.; avoid dosages in excess of 64 mg daily. Severe nausea and vomiting in adults: 8 to 16 mg daily in divided doses; 24 mg occasionally may be necessary; early dosage reduction is desirable.

Route of Administration: Oral

In Vitro Use Guide

Perphenazine (10-100 microM) was administered, either alone or combined with dopamine, to primary mouse neuronal or intact brain culture and to a human neuroblastoma (NB) cell line (SK-N-SH). Cell viability (measured by neutral red and alamar blue), DNA fragmentation (flow cytometry-NB) were determined. Neuroblastoma: perphenazine decreased viability by 87%.

Name

Type

Language

TRILAFON

Preferred Name

English

PERPHENAZINE

Official Name

English

PIPERAZINEETHANOL, 4-(3-(2-CHLORO-10H-PHENOTHIAZIN-10-YL)PROPYL)-

Systematic Name

English

PERPHENAZINE [HSDB]

Common Name

English

4-[3-(2-Chlorophenothiazin-10-yl)propyl]-1-piperazineethanol

Systematic Name

English

PERPHENAZINE [VANDF]

Common Name

English

PERPHENAZINE [USP MONOGRAPH]

Common Name

English

PERPHENAZINE [MART.]

Common Name

English

Perphenazine [WHO-DD]

Common Name

English

PERPHENAZINE MALEATE [JAN]

Common Name

English

PERPHENAZINE [JAN]

Common Name

English

NSC-150866

Code

English

PERPHENAZINE [EP MONOGRAPH]

Common Name

English

ETRAFON-A COMPONENT PERPHENAZINE

Common Name

English

perphenazine [INN]

Common Name

English

PERPHENAZINE [USP-RS]

Common Name

English

FLUPHENAZINE DIHYDROCHLORIDE IMPURITY E [EP IMPURITY]

Common Name

English

PERPHENAZINE [ORANGE BOOK]

Common Name

English

PERPHENAZINE [MI]

Common Name

English

Classification Tree Code System Code

NDF-RT

N0000175746